Project Grant 2151711

Award Date 3/1/22
Completion Date 2/28/23
Dollars Obligated $253K
Federal Grant Program
47.041
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60611, USA
Similar Awards
This National Science Foundation (NSF) Cooperative Agreement award under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $1,000,000 in funding to Amphix Bio Inc. to develop scalable manufacturing methods for a novel supramolecular polymer-based spinal implant. The project aims to enable safer, simpler, and lower-cost spinal fusion surgery by advancing this regenerative medicine technology. The key deliverables include scaling up the production of the...
This Project Grant award of $305,000.00 from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports Plexymer, Inc., a for-profit small business, to develop an artificial intelligence-driven platform for accelerated formulation of antibody therapeutics. The project aims to use AI and robotics to streamline the bioformulation process, potentially reducing the time and materials required to prepare antibody drugs for subcutaneous...
Biosapien Inc. received a $256,000 Project Grant award from the National Science Foundation on May 1, 2021 to develop a novel 3D printed biodegradable mesh delivering active pharmaceutical ingredients in a sustained and localized manner under the Small Business Innovation Research Phase I program. The SBIR Phase I grant supports the proof-of-concept stage of developing Biosapien's technology, with the work expected to be completed by June 30, 2022. The NSF Technology, Innovation, and...
This National Science Foundation (NSF) Cooperative Agreement under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $1,016,000 in funding to Nostopharma LLC to develop an innovative, sustained-release, and biodegradable drug delivery platform for localized treatment of post-traumatic injuries. The goal is to create a medication delivery system using anti-inflammatory nanoparticles embedded with a Hedgehog pathway antagonist, arsenic trioxide, to address unmet...
This Project Grant award of $305,000 from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program will support the development of a novel mammalian cell-based nano-biological coating for implantable medical devices at Novaurum Biosciences Incorporated in Somerville, MA. The project aims to address the critical issue of implant-related infections, which cost the U.S. healthcare system over $8.6 billion annually, by creating a biocompatible and...
The National Science Foundation awarded Diant Pharma Inc. a $256,000 Project Grant under the Engineering (47.041) federal grant program. The grant will support development of an advanced continuous manufacturing system for nucleic acid lipid nanoparticles to improve supply chains for therapeutics and vaccines. Specifically, the small business innovation research Phase I project aims to create a compact, end-to-end manufacturing platform that follows current good manufacturing practices. This...
This Cooperative Agreement award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $1,000,000.00 in funding to Oakgrove Bio LLC to advance a recombinant technology platform that aims to dramatically decrease the cost of manufacturing peptides. The project's broader impact is to accelerate the commercialization of bioactive and structural peptides for applications ranging from antimicrobials and tissue engineering to...
The National Science Foundation (NSF) awarded a $979,298 Cooperative Agreement under its Technology, Innovation, and Partnerships (CFDA 47.084) program to Asante Bio LLC, a small disadvantaged business, to develop a Multi-Axial Filament Winding Process (3DMF) for biomanufacturing high-performance orthobiologic implants for rotator cuff repair. This two-year project aims to optimize the manufacturing, surgical delivery, biomechanical performance, and biocompatibility of the 3DMF implants, which...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Om Therapeutics Inc. will support the development of a system to enable the rapid, scalable, and cost-effective discovery of new medicines using machine learning. The project aims to encapsulate proteins and small molecules in millions of miniaturized compartments to screen for interactions that could identify novel drug candidates. The key innovations include...
The National Science Foundation (NSF) awarded Pearl Bio, Inc., a biotechnology company, a $274,462 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The grant funded the development of a next-generation biomanufacturing platform to engineer new microbial organisms and cellular machinery. This platform enables the incorporation of diverse, non-native components into proteins, creating a new class of biological materials for therapeutic development,...

This $252,906 National Science Foundation project grant supports the development of scalable manufacturing methods for peptide amphiphile molecules by Amphix Bio Inc. The goal is to advance a safer and more affordable alternative to recombinant proteins currently used in spinal fusion surgeries. Over 500,000 such surgeries are performed annually in the U.S. to treat back and neck pain.

While peptide amphiphiles show promise for reducing biological dose needs and offering consistent outcomes, manufacturing them at large scale poses challenges due to sensitivity of the supramolecular self-assembly process. This Phase I Small Business Innovation Research project will apply industry-compatible synthesis methods to improve scalability. The aim is to produce peptide amphiphile assemblies through the new process that achieve equivalent efficacy to laboratory-produced assemblies. If successful, the technology could enable widespread adoption of a spinal fusion therapeutic that is safer and less expensive than options currently on the market. The work is funded through the National Science Foundation's Engineering Directorate (CFDA 47.041) to foster innovation in engineering research.

Generated 1/7/24, 1:06 AM